Attestation Report on the Custody, Management, and Use of Raised Funds
AnHua (2026) Special Letter No. 70024693_H02 Mindray Bio-Medical Electronics Co., Ltd.
To the Board of Directors of Mindray Bio-Medical Electronics Co., Ltd.:
We have been engaged to attest to the accompanying "Special Report on the Custody, Management, and Use of Raised Funds for 2025" (the "Special Report on Raised Funds") of Mindray Bio-Medical Electronics Co., Ltd. The Special Report on Raised Funds has been prepared in accordance with the "Supervisory Regulations for Raised Funds of Listed Companies," the "Shenzhen Stock Exchange Listing Rules for GEM Companies, Chapter 2 - Standardized Operation of GEM Companies," and relevant format guidelines. It is the responsibility of the Board of Directors of Mindray Bio-Medical Electronics Co., Ltd. to ensure that the content of the Special Report on Raised Funds is true, accurate, and complete, and that it contains no false records, misleading statements, or material omissions. Our responsibility is to express an independent attestation opinion based on our performance of the attestation engagement.
We performed the attestation engagement in accordance with the "Other Attestation Services - Attestation Engagements Other Than Audits or Reviews of Historical Financial Information" (CSAE 3101) of the Chinese Certified Public Accountants. This standard requires us to plan and perform the attestation engagement to obtain reasonable assurance about whether the Special Report on Raised Funds is free from material misstatement. In performing the attestation engagement, we carried out procedures including obtaining an understanding, sampling, reconciliation, and other procedures that we considered necessary. We believe that our attestation engagement provides a reasonable basis for our opinion.
We are of the opinion that the Special Report on Raised Funds of Mindray Bio-Medical Electronics Co., Ltd. has been prepared, in all material respects, in accordance with the "Supervisory Regulations for Raised Funds of Listed Companies," the "Shenzhen Stock Exchange Listing Rules for GEM Companies, Chapter 2 - Standardized Operation of GEM Companies," and relevant format guidelines, and truthfully reflects the custody, management, and use of raised funds of Mindray Bio-Medical Electronics Co., Ltd. for 2025.
This report is intended solely for Mindray Bio-Medical Electronics Co., Ltd. to disclose its 2025 annual report and is not applicable for other purposes.
AnHua Certified Public Accountants (Special General Partnership) Certified Public Accountant: Xu Fei China Beijing Certified Public Accountant: Feng Xingzhi March 27, 2026
Special Report on the Custody, Management, and Use of Raised Funds For the Year 2025
I. Basic Situation of Raised Funds
According to the "Approval for the Initial Public Offering of Shares by Mindray Bio-Medical Electronics Co., Ltd." (Zheng Jian Xu Ke [2018] No. 1436) issued by the China Securities Regulatory Commission (hereinafter referred to as the "CSRC"), Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as the "Company") issued 121,600,000 ordinary shares to the public on October 2018, at an issue price of RMB 48.80 per share. The total amount of raised funds was RMB 5,934,080,000.00. After deducting underwriting and sponsorship fees of RMB 138,396,226.41, the actual amount of raised funds received was RMB 5,795,683,773.59. After deducting intermediary fees for the issuance of RMB 43,884,311.43, the net amount of raised funds was RMB 5,751,799,462.16. The raised funds were received on October 10, 2018. The receipt of funds was audited by PricewaterhouseCoopers Zhong Tian LLP (Special General Partnership), which issued the "Capital Verification Report" (PwC Zhong Tian Yan Zi [2018] No. 0626), confirming the receipt of raised funds.
As of December 31, 2025, the Company used RMB 0.00 of raised funds in 2025. The cumulative amount of raised funds used was RMB 4,821,185,702.97. The remaining raised funds of RMB 930,613,759.19 were permanently supplemented to working capital for daily production and operation activities. The balance of unused raised funds is RMB 0.00.